Tyrosine Kinase Inhibitor Induced Pulmonary Artery Hypertension: Reversible with Ponatinib?
Serkan Gokaslan, Ersel Onrat, Cigdem Özer Gokaslan & Ibrahim Etem Dural · International Journal of Medical and Pharmaceutical Case Reports · 2017
Pulmonary arterial hypertension (PAH) is a disease associated with progressive and comprehensive vascular remodeling of small pulmonary arteries. The prognosis of Chronic myelogenous leukemia (CML) has been improved by tyrosine kinase inhibitors (TKIs), which inhibit BCR/ABL kina...
Open access
Research Article
10.9734/IJMPCR/2017/34110